The Food and Drug Administration (FDA) has approved Hyftor™ (sirolimus topical gel) for the treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC) in patients 6 years ...

The FDA approved sirolimus 0.2% gel (Hyftor) as the first topical treatment for facial angiofibroma associated with tuberous sclerosis complex (TSC), Nobelpharma announced. The approved indication ...

Hyftor ™ (sirolimus topical gel) is now available for the treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC) in patients 6 years of age and older.. The approval ...

The FDA approved topical Hyftor for the treatment of facial angiofibroma in patients who have tuberous sclerosis complex, Nobelpharma America LLC announced in a press release.Hyftor (sirolimus ...

Today the TSC Alliance® applauds the U.S. Food and Drug Administration’s (FDA’s) approval of HYFTOR™, which is the first FDA-approved topical treatment for facial angiofibromas in adults ...

Facial angiofibromas affect most patients with the inherited disorder TSC. Traditional treatment options for the lesions, which can impair vision and affect quality of life, include dermabrasion ...

Nobelpharma America is launching FACE FORWARD, a website focused on education and awareness of a rare disease known as facial angiofibroma, which is an aspect of tuberous sclerosis complex (TSC).

Medically reviewed by Kashif J. Piracha, MD Fibromas are benign (noncancerous) tumors made of fibrous connective tissues—tissue made of tough protein fibers that protect and support muscles, bones, ...

Potential Positives. Quoin Pharmaceuticals has filed U.S. and International patent applications for novel topical rapamycin formulations, potentially positioning itself as a pioneer in treating ...